Compare Stocks → the most reliable asset on earth is making a comeback (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:AVDLNASDAQ:KALANASDAQ:UMRXNASDAQ:URGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsAVDLAvadel Pharmaceuticals$16.89+0.3%$14.85$8.00▼$17.47$1.53B1.561.64 million shs510,834 shsKALAKALA BIO$7.84-0.1%$7.35$5.10▼$19.57$21.14M-1.8617,576 shs9,908 shsUMRXCogent Biosciences$6.72+3.1%$10.50$0.29▼$3.72$285.39M3.931.22 million shs2.07 million shsURGNUroGen Pharma$15.00+0.3%$16.84$8.00▼$24.13$350.87M1.09434,201 shs175,784 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+60.08%AVDLAvadel Pharmaceuticals+0.30%-1.17%+26.90%+19.62%+89.99%KALAKALA BIO-0.13%-0.25%+9.65%+12.00%-47.10%UMRXCogent Biosciences+3.07%+0.75%-10.40%+11.07%-35.57%URGNUroGen Pharma+0.27%+0.40%-19.31%0.00%+69.88%A lot of people are making this costly mistake (Ad)You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next oneMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals3.9249 of 5 stars4.52.00.00.03.93.30.6KALAKALA BIO4.4199 of 5 stars3.53.00.04.42.11.71.3UMRXCogent BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AURGNUroGen Pharma3.9617 of 5 stars3.50.00.04.52.03.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.25Hold$17.50∞ UpsideAVDLAvadel Pharmaceuticals3.00Buy$22.5733.64% UpsideKALAKALA BIO3.00Buy$22.00180.61% UpsideUMRXCogent BiosciencesN/AN/AN/AN/AURGNUroGen Pharma3.00Buy$46.67211.11% UpsideCurrent Analyst RatingsLatest UMRX, AGLE, AVDL, KALA, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/15/2024URGNUroGen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $34.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/6/2024AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00AVDLAvadel Pharmaceuticals$27.96M54.72N/AN/A$0.98 per share17.23KALAKALA BIO$3.89M5.42N/AN/A$11.12 per share0.71UMRXCogent Biosciences$22.50M12.68N/AN/A$1.04 per share6.46URGNUroGen Pharma$82.71M4.25N/AN/A($2.78) per share-5.40Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/AAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A20.35N/AN/A-198.06%-84.51%5/2/2024 (Estimated)KALAKALA BIO-$44.82M-$22.73N/AN/AN/AN/A-259.42%-64.39%3/29/2024 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/AURGNUroGen Pharma-$102.24M-$3.73N/AN/AN/A-123.61%N/A-70.48%5/9/2024 (Estimated)Latest UMRX, AGLE, AVDL, KALA, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023URGNUroGen Pharma-$0.67-$0.72-$0.05-$0.72$22.30 million$23.53 million 3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59AVDLAvadel PharmaceuticalsN/A3.643.36KALAKALA BIO3.365.625.62UMRXCogent Biosciences0.182.902.90URGNUroGen PharmaN/A5.425.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/AAVDLAvadel Pharmaceuticals69.19%KALAKALA BIO24.61%UMRXCogent Biosciences26.39%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%AVDLAvadel Pharmaceuticals4.00%KALAKALA BIO13.40%UMRXCogent Biosciences31.50%URGNUroGen Pharma11.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableKALAKALA BIO342.69 million2.33 millionNot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableURGNUroGen Pharma19823.45 million20.84 millionOptionableUMRX, AGLE, AVDL, KALA, and URGN HeadlinesSourceHeadlineHead-To-Head Survey: InMed Pharmaceuticals (NASDAQ:INM) and UroGen Pharma (NASDAQ:URGN)americanbankingnews.com - March 24 at 1:30 AMUroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stockinsidertrades.com - March 22 at 6:30 AMMark Schoenberg Sells 12,000 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stockmarketbeat.com - March 20 at 7:50 PMUroGen Pharma Ltd. to Post Q1 2024 Earnings of ($0.94) Per Share, HC Wainwright Forecasts (NASDAQ:URGN)americanbankingnews.com - March 20 at 6:18 AMUroGen Pharma Ltd. to Post Q1 2025 Earnings of ($0.73) Per Share, HC Wainwright Forecasts (NASDAQ:URGN)americanbankingnews.com - March 20 at 3:58 AMUroGen Pharma Ltd. (NASDAQ:URGN) to Post Q1 2025 Earnings of ($0.73) Per Share, HC Wainwright Forecastsmarketbeat.com - March 19 at 7:14 AMUroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwrightamericanbankingnews.com - March 19 at 5:00 AMUroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimeramericanbankingnews.com - March 19 at 2:32 AMUroGen: All Eyes On UGN-102seekingalpha.com - March 18 at 11:48 PMOppenheimer Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $34.00marketbeat.com - March 18 at 6:32 PMUroGen Pharma (NASDAQ:URGN) Rating Reiterated by HC Wainwrightmarketbeat.com - March 18 at 5:32 PMUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 17 at 5:45 PMUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 2:14 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)markets.businessinsider.com - March 14 at 11:32 PMUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finanznachrichten.de - March 14 at 6:32 PMUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challengesfinance.yahoo.com - March 14 at 1:26 PMURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 1:03 PMUrogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 14 at 10:10 AMUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finance.yahoo.com - March 14 at 8:25 AMUroGen Pharma earnings preview: what to expectmarkets.businessinsider.com - March 13 at 12:58 PMSchonfeld Strategic Advisors LLC Purchases Shares of 130,200 UroGen Pharma Ltd. (NASDAQ:URGN)marketbeat.com - March 9 at 5:42 AMUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 8 at 8:00 AMUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024finance.yahoo.com - March 4 at 9:33 AM3 Biotech Stocks Climbing the Ranks to Watchstocknews.com - March 1 at 12:11 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?Abercrombie & Fitch Stock Just Got an Upgrade to Beat Its PeersMarch 6, 2024 6:07 AMView Abercrombie & Fitch Stock Just Got an Upgrade to Beat Its PeersAll Headlines Company DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Avadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Cogent BiosciencesNASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.UroGen PharmaNASDAQ:URGNUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.